Beijing SL Pharmaceutical Co., Ltd.
Symbole: 002038.SZ
SHZ
8.62
CNYPrix du marché aujourd'hui
31.0841
Ratio P/E
2.4867
Ratio PEG
8.86B
Cap MRK
- 0.01%
Rendement DIV
Beijing SL Pharmaceutical Co., Ltd. (002038-SZ) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5056.78 | 2133 | 739.9 | 990.2 | |||||||||||||||||||||||
balance-sheet.row.short-term-investments | 2289.51 | 1449.2 | 144.9 | 162.4 | |||||||||||||||||||||||
balance-sheet.row.net-receivables | 1134.59 | 236.2 | 406.4 | 534 | |||||||||||||||||||||||
balance-sheet.row.inventory | 625.05 | 144.5 | 136.8 | 124.8 | |||||||||||||||||||||||
balance-sheet.row.other-current-assets | 2585.99 | 126.3 | 714.5 | 648.7 | |||||||||||||||||||||||
balance-sheet.row.total-current-assets | 9402.41 | 2640 | 1997.7 | 2297.7 | |||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 2044.8 | 538.4 | 527.3 | 604 | |||||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.intangible-assets | 4425.3 | 1143.7 | 978.5 | 872.8 | |||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 4425.3 | 1143.7 | 978.5 | 872.8 | |||||||||||||||||||||||
balance-sheet.row.long-term-investments | 5601.25 | 1587.3 | 1295.1 | 1241.3 | |||||||||||||||||||||||
balance-sheet.row.tax-assets | 77.69 | 0 | 39.5 | 27.7 | |||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3192.71 | 368.4 | 1037.7 | 717 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 15341.75 | 3637.8 | 3878.2 | 3462.7 | |||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.total-assets | 24744.16 | 6277.8 | 5875.8 | 5760.5 | |||||||||||||||||||||||
balance-sheet.row.account-payables | 778.6 | 213.2 | 176.2 | 191.4 | |||||||||||||||||||||||
balance-sheet.row.short-term-debt | 46.32 | 37.6 | -27.9 | 0.2 | |||||||||||||||||||||||
balance-sheet.row.tax-payables | 11.48 | 0 | 9 | 16.3 | |||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 2.2 | |||||||||||||||||||||||
Deferred Revenue Non Current | 185.63 | 47 | 51.4 | 56.2 | |||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 223.42 | - | - | - | |||||||||||||||||||||||
balance-sheet.row.other-current-liab | 379.81 | 107.3 | 112.7 | 1.6 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 362.01 | 47.4 | 107.8 | 109.3 | |||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 2.2 | |||||||||||||||||||||||
balance-sheet.row.total-liab | 1621.95 | 420.7 | 396.6 | 434.2 | |||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.common-stock | 4109.4 | 1027.3 | 1027.3 | 1027.3 | |||||||||||||||||||||||
balance-sheet.row.retained-earnings | 16182.54 | 4077.8 | 3763.8 | 3632.1 | |||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2743.99 | 695.1 | 676.5 | 651.9 | |||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0.86 | 0.4 | 0.4 | 0.1 | |||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 23036.79 | 5800.6 | 5468.1 | 5311.5 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 24744.16 | 6277.8 | 5875.8 | 5760.5 | |||||||||||||||||||||||
balance-sheet.row.minority-interest | 38.37 | 9.4 | 11.2 | 14.7 | |||||||||||||||||||||||
balance-sheet.row.total-equity | 23075.16 | 5810 | 5479.2 | 5326.2 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 24744.16 | - | - | - | |||||||||||||||||||||||
Total Investments | 7890.75 | 3036.4 | 1440.1 | 1403.6 | |||||||||||||||||||||||
balance-sheet.row.total-debt | 75.19 | 37.6 | 0 | 2.5 | |||||||||||||||||||||||
balance-sheet.row.net-debt | -2692.08 | -646.2 | -595 | -825.4 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 284.9 | 228.3 | 421.3 | 361.5 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 6.41 | 113.9 | 99.8 | 89.5 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.3 | 14.4 | 25.6 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 6.3 | -14.4 | -25.6 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 15.41 | 113.7 | 129.1 | 197.9 | ||||||||||||||||||||
cash-flows.row.account-receivables | 19.66 | 82.9 | 108.6 | 198.8 | ||||||||||||||||||||
cash-flows.row.inventory | -4.25 | 0.6 | -11.5 | -3.7 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 36.6 | 17.5 | -22.7 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.3 | 14.4 | 25.6 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 269.47 | -66.1 | -185.6 | -233.1 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 481.62 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -213.1 | -163.5 | -236.9 | -255.9 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.01 | -3.4 | 16.5 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | -582.01 | -1247.4 | -1061 | -1517.2 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 487.59 | 896.1 | 1092.6 | 964.3 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | -71.42 | -22.2 | -9 | -33.3 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -383.53 | -540.4 | -197.8 | -842.1 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -11 | -5.6 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -102.7 | -102.9 | -205.8 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 10.6 | 4.5 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -110.25 | -102.7 | -103.3 | -206.9 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.03 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | -153.55 | -253.2 | 163.5 | -633.1 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 2465.46 | 527.2 | 780.4 | 617 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2619.01 | 780.4 | 617 | 1250.1 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 481.62 | 389.8 | 464.6 | 415.8 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | -213.1 | -163.5 | -236.9 | -255.9 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 268.53 | 226.3 | 227.7 | 159.9 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 962.21 | 1008.3 | 1050.2 | 1214.8 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 238.91 | 305.5 | 157 | 183.6 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | 723.3 | 702.8 | 893.2 | 1031.2 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 166.1 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 19.27 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 214.73 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | -0.99 | -1 | 99.2 | 82.7 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 498.87 | 491.6 | 711.2 | 776.1 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 737.77 | 797.1 | 868.2 | 959.7 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 14.77 | 14.2 | 15.2 | 16.8 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0.2 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 214.73 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 53.63 | 241.5 | -4 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -0.99 | -1 | 99.2 | 82.7 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 53.63 | 241.5 | -4 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0.2 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 52.83 | 145.7 | 161 | 134.8 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 348.88 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | 239.31 | 211.1 | 263.3 | 457.5 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | 292.94 | 452.6 | 259.4 | 457.8 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 22.25 | 49.9 | 31 | 36.5 | |||||||||||||||||||||||
income-statement-row.row.net-income | 284.9 | 416.7 | 234.4 | 425.9 |
Questions fréquemment posées
Quel est le total de Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) de l'actif total?
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) Le total des actifs est 6277761845.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est 482153895.000.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.752.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est 0.261.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est 0.296.
Quel est le revenu total de l'entreprise?
Le revenu total est 0.249.
Qu'est-ce que Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est 416691942.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 37593280.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 491631884.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 643139595.000.